Demerol (meperidine) is a Schedule II controlled substance under the Controlled Substances Act. This is the second-most restrictive category, reserved for drugs with a high potential for abuse that may lead to severe psychological or physical dependence. It sits in the same schedule as oxycodone, fentanyl, hydromorphone, and methadone.
What Schedule II Means for Prescriptions
Schedule II drugs carry the tightest prescribing rules of any medication that can still be legally prescribed. The most significant restriction: refills are prohibited. Every time you need more, your prescriber must issue a brand-new prescription. A pharmacist cannot simply authorize another fill the way they could with a lower-schedule medication.
Your doctor can write multiple prescriptions at once covering up to a 90-day supply, but each individual prescription must include a specific earliest fill date. This allows ongoing pain management without requiring a new office visit every few days, while still maintaining oversight. In emergency situations, a pharmacist can accept a phone-in order for a Schedule II drug, but the prescriber must follow up with a written prescription within seven days.
What Demerol Is Used For
Demerol is an opioid pain reliever approved for pain severe enough to require opioid treatment, specifically when other pain medications haven’t worked well enough or can’t be tolerated. It’s available as tablets, an oral solution, and a syrup.
In terms of strength, Demerol is considerably weaker than morphine on a milligram-for-milligram basis. It takes roughly 75 mg of injectable Demerol to match 10 mg of injectable morphine, and about 300 mg by mouth to equal 30 mg of oral morphine. This lower potency, combined with its safety concerns, is one reason it has fallen out of favor.
Why Demerol Has Declined in Use
Despite being one of the most widely recognized opioid brand names, Demerol is now rarely the first choice in clinical settings. The VA health system, among other institutions, has actively restricted its use. The core issue is a byproduct your body creates when it breaks down the drug.
When your liver processes meperidine, it converts it into a compound called normeperidine. This byproduct lingers in the body far longer than the drug itself, with a half-life of 15 to 20 hours compared to just 2 to 4 hours for meperidine. That means normeperidine builds up with repeated doses. While it provides only about half the pain relief of the original drug, it is twice as potent at triggering nervous system problems: mood changes, anxiety, tremors, muscle jerking, and in serious cases, seizures. The risk of delirium is also higher with Demerol than with other opioid painkillers.
People with kidney problems face even greater danger because normeperidine’s half-life nearly doubles to around 34 hours when the kidneys aren’t clearing it efficiently. Liver disease creates a similar problem, with both the drug and its byproduct accumulating to toxic levels. For these reasons, Demerol is contraindicated in patients with significant kidney or liver impairment.
Because other opioids offer similar pain relief with a lower risk of these complications, most guidelines now recommend choosing alternatives over Demerol, particularly for older adults who are more vulnerable to delirium and seizures.
A Dangerous Drug Interaction
Demerol carries a specific and potentially fatal interaction that sets it apart from many other opioids. It must never be taken by anyone currently using, or who has used within the past 14 days, a type of antidepressant known as an MAO inhibitor. Even standard therapeutic doses of Demerol have triggered severe and sometimes fatal reactions in people with recent MAO inhibitor exposure.
These reactions can go in two directions. Some patients develop symptoms resembling a massive overdose: coma, dangerously slow breathing, and plummeting blood pressure. Others experience the opposite, a syndrome of hyperexcitability with convulsions, racing heart rate, and spiking body temperature. Serotonin syndrome, marked by agitation, sweating, tremors, and impaired consciousness, can also occur. The unpredictability of these reactions is part of what makes the combination so dangerous.
Addiction and Dependence Risk
As a Schedule II opioid, Demerol carries a high potential for both physical dependence and addiction. Its capacity to produce tolerance and dependence is comparable to morphine and other opioids in its class. With repeated use, your body adjusts to the drug’s presence, and stopping abruptly can trigger withdrawal symptoms.
Physical dependence, which is a predictable biological response, is distinct from addiction, which involves compulsive drug-seeking behavior and use for purposes beyond pain relief. Both risks are real with Demerol, and they are the central reason the drug carries Schedule II restrictions rather than a less restrictive classification.